Cassava Sciences IncNASDAQ:SAVA
- LAST PRICE11.7330
- TODAY'S CHANGE (%)-0.6170 (-4.9960%)
- Bid / Lots11.7300/ 2
- Ask / Lots11.7500/ 4
- Open / Previous Close10.6400 / 12.3500
- Day Range
- 52 Week Range
- Volume6,535,981
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SAVA |
|---|---|---|
| 09:32 ET | 457342 | 10.42 |
| 09:34 ET | 190077 | 10.31 |
| 09:36 ET | 205126 | 10.89 |
| 09:38 ET | 236516 | 11.14 |
| 09:39 ET | 240944 | 11.13 |
| 09:41 ET | 200603 | 11.25 |
| 09:43 ET | 155486 | 11.25 |
| 09:45 ET | 69319 | 11.105 |
| 09:48 ET | 73007 | 11.3 |
| 09:50 ET | 86531 | 11.24 |
| 09:52 ET | 79109 | 11.08 |
| 09:54 ET | 99961 | 10.98 |
| 09:56 ET | 98734 | 11.15 |
| 09:57 ET | 28359 | 11.2695 |
| 09:59 ET | 188101 | 11.74 |
| 10:01 ET | 90357 | 11.42 |
| 10:03 ET | 56939 | 11.54 |
| 10:06 ET | 33684 | 11.5392 |
| 10:08 ET | 36521 | 11.53 |
| 10:10 ET | 25955 | 11.5 |
| 10:12 ET | 20238 | 11.38 |
| 10:14 ET | 23666 | 11.325 |
| 10:15 ET | 26858 | 11.38 |
| 10:17 ET | 53588 | 11.5001 |
| 10:19 ET | 30822 | 11.305 |
| 10:21 ET | 81009 | 11.1495 |
| 10:24 ET | 42072 | 11.27 |
| 10:26 ET | 48446 | 11.3595 |
| 10:28 ET | 20654 | 11.34 |
| 10:30 ET | 29144 | 11.415 |
| 10:32 ET | 48092 | 11.52 |
| 10:33 ET | 33555 | 11.5342 |
| 10:35 ET | 21367 | 11.525 |
| 10:37 ET | 36436 | 11.57 |
| 10:39 ET | 67294 | 11.485 |
| 10:42 ET | 24079 | 11.49 |
| 10:44 ET | 19252 | 11.56 |
| 10:46 ET | 29620 | 11.5201 |
| 10:48 ET | 23779 | 11.38 |
| 10:50 ET | 22225 | 11.38 |
| 10:51 ET | 35402 | 11.32 |
| 10:53 ET | 14211 | 11.39 |
| 10:55 ET | 16032 | 11.4642 |
| 10:57 ET | 19694 | 11.55 |
| 11:00 ET | 35216 | 11.57 |
| 11:02 ET | 59684 | 11.71 |
| 11:04 ET | 37042 | 11.7159 |
| 11:06 ET | 120135 | 11.76 |
| 11:08 ET | 64024 | 11.785 |
| 11:09 ET | 22074 | 11.79 |
| 11:11 ET | 59588 | 11.75 |
| 11:13 ET | 11255 | 11.78 |
| 11:15 ET | 8781 | 11.7301 |
| 11:18 ET | 56607 | 11.81 |
| 11:20 ET | 36953 | 11.81 |
| 11:22 ET | 17058 | 11.733 |
Today
DJ Cassava Sciences Cut to Hold From Buy by Jones Trading, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesDJ Cassava Sciences Cut to Neutral From Buy by HC Wainwright & Co., from 4 hours ago by Dow Jones
4 hours ago by Dow Jones
Jun 28, 2024
DJ Cassava Sciences Shares Plunge on Indictment Against Former Advisor -- Barrons.com, from 6:33PM ET on Friday Jun 28, 2024 by Dow Jones
6:33PM ET on Friday Jun 28, 2024 by Dow JonesDJ Cassava Sciences Adviser Indicted on Fraud Charges -- 2nd Update, from 6:14PM ET on Friday Jun 28, 2024 by Dow Jones
6:14PM ET on Friday Jun 28, 2024 by Dow JonesDJ Cassava Sciences Adviser Indicted on Fraud Charges -- Update, from 4:21PM ET on Friday Jun 28, 2024 by Dow Jones
4:21PM ET on Friday Jun 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cassava Sciences Inc | 592.5M | -10.0x | --- |
Replimune Group Inc | 603.8M | -2.8x | --- |
Mineralys Therapeutics Inc | 580.9M | -5.5x | --- |
Olema Pharmaceuticals Inc | 605.2M | -5.3x | --- |
GH Research PLC | 606.6M | -17.1x | --- |
Phathom Pharmaceuticals Inc | 602.9M | -2.4x | --- |
Company Information
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
Contact Information
- Headquarters
- 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300AUSTIN, TX, United States 78731
- Phone
- 512-501-2444
- Fax
- 512-614-0414
Executives
- Chairman of the Board, President, Chief Executive Officer
- Remi Barbier
- Chief Financial Officer
- Eric Schoen
- Senior Vice President, General Counsel
- R. Christopher Cook
- Chief Medical Officer
- James Kupiec
- Lead Independent Director
- Sanford Robertson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $592.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 48.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.58 |
EPS | $-1.17 |
Book Value | $3.25 |
P/E Ratio | -10.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
